The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Nov. 24, 2009
Filed:
Jul. 14, 2006
Solomon Ungashe, Fremont, CA (US);
Zheng Wei, Union City, CA (US);
Arindrajit Basak, Mountain View, CA (US);
Trevor T. Charvat, San Jose, CA (US);
Wei Chen, Freemont, CA (US);
Jeff Jin, Fremont, CA (US);
Jimmie Moore, Redwood City, CA (US);
Yibin Zeng, San Mateo, CA (US);
Sreenivas Punna, Sunnyvale, CA (US);
Daniel Dairaghi, Palo Alto, CA (US);
Derek Hansen, Half Moon Bay, CA (US);
Andrew M. K. Pennell, San Francisco, CA (US);
John J. Wright, Redwood City, CA (US);
Solomon Ungashe, Fremont, CA (US);
Zheng Wei, Union City, CA (US);
Arindrajit Basak, Mountain View, CA (US);
Trevor T. Charvat, San Jose, CA (US);
Wei Chen, Freemont, CA (US);
Jeff Jin, Fremont, CA (US);
Jimmie Moore, Redwood City, CA (US);
Yibin Zeng, San Mateo, CA (US);
Sreenivas Punna, Sunnyvale, CA (US);
Daniel Dairaghi, Palo Alto, CA (US);
Derek Hansen, Half Moon Bay, CA (US);
Andrew M. K. Pennell, San Francisco, CA (US);
John J. Wright, Redwood City, CA (US);
ChemoCentryx, Inc., Mountain View, CA (US);
Abstract
Compounds are provided that act as potent antagonists of the CCR2 receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR2. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR2-mediated diseases, and as controls in assays for the identification of CCR2 antagonists.